Answers are grounded in this paper and cite their sources.
Case series demonstrates optimization of thiopurine therapy through genetic testing and drug monitoring, implying reduced toxicity risk.
Thiopurines, a widely used immunosuppressant for autoimmune and inflammatory condition, is associated with potentially severe adverse effects, particularly myelosuppression. Genetic polymorphisms in thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) can largely predict the risk of thiopurine-induced toxicity. Therapeutic drug monitoring (TDM) of its metabolites, particularly 6-thioguanine nucleotides (6-TGN), may help to optimize dosing and prevent toxicity. A case series of four Indian patients who developed azathioprine-related myelosuppression is presented. Each patient either expressed a low to intermediate TPMT enzyme activity or a NUDT15 c.415C>T (p.R139C) polymorphism. In all cases, 6-TGN concentrations were measured to assess thiopurine exposure. TPMT phenotyping, NUDT15 genotyping, and 6-TGN monitoring represents an integrated approach to optimize thiopurine therapy.
No takes yet. Share an insight, caveat, or question.
Joseph et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: